MA42930A - Traitement de maladies neurodégénératives - Google Patents
Traitement de maladies neurodégénérativesInfo
- Publication number
- MA42930A MA42930A MA042930A MA42930A MA42930A MA 42930 A MA42930 A MA 42930A MA 042930 A MA042930 A MA 042930A MA 42930 A MA42930 A MA 42930A MA 42930 A MA42930 A MA 42930A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- neurodegenerative diseases
- neurodegenerative
- diseases
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1516905.5A GB201516905D0 (en) | 2015-09-24 | 2015-09-24 | Treatment of Neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42930A true MA42930A (fr) | 2018-08-01 |
Family
ID=54544061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042930A MA42930A (fr) | 2015-09-24 | 2016-09-23 | Traitement de maladies neurodégénératives |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180263992A1 (fr) |
| EP (1) | EP3352759A1 (fr) |
| JP (1) | JP6893917B2 (fr) |
| KR (1) | KR20180056695A (fr) |
| CN (1) | CN108025005A (fr) |
| AU (1) | AU2016329005A1 (fr) |
| BR (1) | BR112018005855A2 (fr) |
| CA (1) | CA2999390A1 (fr) |
| EA (1) | EA201890647A1 (fr) |
| GB (1) | GB201516905D0 (fr) |
| MA (1) | MA42930A (fr) |
| MX (1) | MX2018003619A (fr) |
| WO (1) | WO2017051188A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170335324A1 (en) | 2014-11-12 | 2017-11-23 | The General Hospital Corporation | Methods for treating neurodegenerative diseases |
| GB201714303D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatment of neurodegenerative diseases |
| GB201714311D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatment of neurodegenerative diseases |
| GB201714316D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatement of neurodegenerative diseases |
| GB201714307D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatment of neurodegenerative diseases |
| CN108853111B (zh) * | 2018-08-07 | 2020-06-05 | 浙江大学 | 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用 |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| CN114099509B (zh) * | 2020-08-26 | 2023-12-08 | 长庚大学 | 一种酪氨酸激酶抑制剂在制造用以治疗因炎性体激活所致相关疾病的药物中的用途 |
| CN113694047A (zh) * | 2021-08-31 | 2021-11-26 | 杭州师范大学 | β-石竹烯在制备抗肿瘤药物中的应用 |
| WO2025152803A1 (fr) * | 2024-01-17 | 2025-07-24 | 四川大学 | Polypeptide ciblant traf6 et son utilisation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US257403A (en) * | 1882-05-02 | Electric lighting apparatus | ||
| US62342A (en) * | 1867-02-26 | Improved tool for the manufacture of paper bags | ||
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| EP1501511A4 (fr) * | 2002-05-06 | 2006-06-07 | Univ Washington | Methodes de traitement du glaucome et d'autres etats induits par l'expression de nos-2 par inhibition de la voie egfr |
| JP4328500B2 (ja) * | 2002-07-25 | 2009-09-09 | 独立行政法人農業・食品産業技術総合研究機構 | 中枢神経細胞突起再生剤及びその薬理作用を有する高機能性製品 |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| US7547794B2 (en) * | 2003-04-03 | 2009-06-16 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| HUE038707T2 (hu) * | 2004-02-09 | 2018-11-28 | Mitsubishi Tanabe Pharma Corp | Új terápiás szer amiotrófiás laterálszklerózisra (ALS) vagy ALS okozta betegségekre |
| ZA200706804B (en) * | 2005-02-03 | 2008-10-29 | Gen Hospital Corp | Method for treating gefitinib resistant cancer |
| US7449442B2 (en) * | 2005-07-12 | 2008-11-11 | Children's Medical Center Corporation | EGFR inhibitors promote axon regeneration |
| JP2008061505A (ja) * | 2006-09-04 | 2008-03-21 | Hisamitsu Pharmaceut Co Inc | 筋萎縮性側索硬化症の治療剤のスクリーニング方法 |
| WO2010017541A2 (fr) * | 2008-08-08 | 2010-02-11 | The Johns Hopkins University | Compositions et procédés de traitement d'une maladie dégénérative du système nerveux |
| AU2010281524A1 (en) * | 2009-08-06 | 2012-02-23 | Neuraltus Pharmaceuticals, Inc. | Treatment of macrophage-related disorders |
| MX2012004638A (es) * | 2009-10-22 | 2012-07-04 | Genentech Inc | Modulacion de degeneracion de axones. |
| EP2877159B8 (fr) * | 2012-07-27 | 2018-02-14 | Izumi Technology, LLC. | Compositions inhibitrices d'écoulement et méthodes de traitement à l'aide celles-ci |
-
2015
- 2015-09-24 GB GBGB1516905.5A patent/GB201516905D0/en not_active Ceased
-
2016
- 2016-09-23 WO PCT/GB2016/052970 patent/WO2017051188A1/fr not_active Ceased
- 2016-09-23 US US15/762,657 patent/US20180263992A1/en not_active Abandoned
- 2016-09-23 BR BR112018005855A patent/BR112018005855A2/pt not_active Application Discontinuation
- 2016-09-23 EP EP16775842.4A patent/EP3352759A1/fr not_active Withdrawn
- 2016-09-23 KR KR1020187010855A patent/KR20180056695A/ko not_active Withdrawn
- 2016-09-23 MA MA042930A patent/MA42930A/fr unknown
- 2016-09-23 AU AU2016329005A patent/AU2016329005A1/en not_active Abandoned
- 2016-09-23 JP JP2018516056A patent/JP6893917B2/ja not_active Expired - Fee Related
- 2016-09-23 MX MX2018003619A patent/MX2018003619A/es unknown
- 2016-09-23 EA EA201890647A patent/EA201890647A1/ru unknown
- 2016-09-23 CN CN201680056062.1A patent/CN108025005A/zh active Pending
- 2016-09-23 CA CA2999390A patent/CA2999390A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180263992A1 (en) | 2018-09-20 |
| AU2016329005A1 (en) | 2018-04-19 |
| CA2999390A1 (fr) | 2017-03-30 |
| EA201890647A1 (ru) | 2018-09-28 |
| BR112018005855A2 (pt) | 2018-10-16 |
| WO2017051188A1 (fr) | 2017-03-30 |
| EP3352759A1 (fr) | 2018-08-01 |
| KR20180056695A (ko) | 2018-05-29 |
| CN108025005A (zh) | 2018-05-11 |
| MX2018003619A (es) | 2018-08-01 |
| JP6893917B2 (ja) | 2021-06-23 |
| GB201516905D0 (en) | 2015-11-11 |
| JP2018534259A (ja) | 2018-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3488001A4 (fr) | Traitement du cancer | |
| FR25C1031I1 (fr) | Traitement de maladies cholestatiques intrahepatiques | |
| EP3388004A4 (fr) | Instrument de traitement | |
| EP3448875A4 (fr) | Compositions pour le traitement de maladies | |
| EP3370721A4 (fr) | Traitement de l'ostéoarthrite | |
| EP3273955A4 (fr) | Traitement de maladies respiratoires | |
| EP3448263A4 (fr) | Traitement électrothérapeutique | |
| MA48996A (fr) | Méthodes de traitement de maladies neurodégénératives | |
| MA42930A (fr) | Traitement de maladies neurodégénératives | |
| EP3658139A4 (fr) | Méthodes de traitement de maladies hépatiques | |
| EP3261641A4 (fr) | Traitement de la pancréatite | |
| EP3373962A4 (fr) | Compositions et méthodes de traitement de maladies auto-immunes et de cancers | |
| EP3375108A4 (fr) | Traitement dewlan | |
| EP3364974A4 (fr) | Modulateurs de maladies impliquant des télomères | |
| EP3307280A4 (fr) | Traitement de dysfonction sexuelle | |
| MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
| EP3316887A4 (fr) | Inhibiteurs de gls1 pour le traitement de maladies | |
| IL257764B (en) | Methods for treatment of diseases | |
| EP3344258A4 (fr) | Traitement de maladies auto-immunes et de maladies auto-inflammatoires | |
| MA41462A (fr) | Méthode de traitement de maladies | |
| FR3039368B1 (fr) | Procede de traitement cosmetique | |
| EP3347032A4 (fr) | Traitement de l'ascite | |
| EP3328384A4 (fr) | Traitement de la fibrose | |
| EP3458062A4 (fr) | Traitement de la douleur | |
| EP3364965A4 (fr) | Méthodes et compositions pour le traitement de maladies neurodégénératives |